Newstral
Samsung Bioepis
- The First Biosimilar Disputes at the Unified Patent Court (UPC)jdsupra.com
- Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Ordersjdsupra.com
- MDL Panel Grants Transfer of Aflibercept BPCIA Casejdsupra.com
- EYLEA® IPR Appeals Filedjdsupra.com
- Updates on Aflibercept BPCIA Litigation - March 2024jdsupra.com
- Post-Trial Updates on Regeneron v. Mylan (Aflibercept) BPCIA Litigationjdsupra.com
- First High-Concentration Humira® Interchangeable, Alvotech and Teva’s Simlandi®, Approved in the U.S.jdsupra.com
- Year in Review: Top Legal Developments of 2023jdsupra.com
- 2023 Post-Grant Annual Reportjdsupra.com
- Updates on Aflibercept BPCIA Litigationjdsupra.com
- EYLEA® (aflibercept) and Soliris® (eculizumab) IPR Updatesjdsupra.com
- EYLEA® (aflibercept) IPR and BPCIA Litigation Updatesjdsupra.com
- Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigationjdsupra.com
- Stelara® Biosimilar Updates: IPR Petition Challenging U.S. Patent No. 10,961,307 Filed and SB17 Settlement and Launch Date Announcedjdsupra.com
- Regeneron Sues Formycon AG for Proposed Biosimilar of EYLEA in West Virginia District Courtjdsupra.com
- Update on Ophthalmic Anti-VEGF Therapeuticsjdsupra.com
- Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patentjdsupra.com
- Organon Launches HERCEPTIN and AVASTIN Biosimilars in Canadajdsupra.com
- GTrastuzumab Emtansine for Injection Market, Global Outlook and Forecast 2022-2028galleonnews.com
- Mayor and City Council of Baltimore v. AbbVie Inc. (7th Cir. 2022)jdsupra.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.